4//SEC Filing
Lees-Rolfe Garth 4
Accession 0000950170-24-040358
CIK 0001750149other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 5:14 PM ET
Size
5.4 KB
Accession
0000950170-24-040358
Insider Transaction Report
Form 4
Lees-Rolfe Garth
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2024-04-01+90,000→ 90,000 totalExercise: $2.16Exp: 2031-04-01→ Common Stock (90,000 underlying)
Footnotes (1)
- [F1]One-third of the options will vest and become exercisable on April 1, 2025, one-third of the options will vest and become exercisable on April 1, 2026, and one-third of the options will vest and become exercisable on April 1, 2027, in each case subject to continued employment through each such vesting date.
Documents
Issuer
Inhibikase Therapeutics, Inc.
CIK 0001750149
Entity typeother
Related Parties
1- filerCIK 0002017374
Filing Metadata
- Form type
- 4
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 5:14 PM ET
- Size
- 5.4 KB